Last reviewed · How we verify
CREON (PROTEASE))
CREON (generic name: PROTEASE)) is a drug developed by ABBVIE. It is currently FDA-approved.
At a glance
| Generic name | PROTEASE) |
|---|---|
| Sponsor | ABBVIE |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Headache
- Contusion
- Cough
- Early Satiety
- Abdominal Pain
- Steatorrhea
- Nausea
- Diarrhea
- Flatulence
- Abdominal Distension
- Constipation
Serious adverse events
- Fibrosing Colonopathy
- Distal Intestinal Obstruction Syndrome
- Anaphylaxis
- Asthma
- Hypersensitivity Reactions
- Hives
- Urticaria
- Blurred Vision
- Myalgia
- Muscle Spasm
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CREON CI brief — competitive landscape report
- CREON updates RSS · CI watch RSS
- ABBVIE portfolio CI
Frequently asked questions about CREON
What is CREON?
CREON (PROTEASE)) is a pharmaceutical drug developed by ABBVIE.
Who makes CREON?
CREON is developed and marketed by ABBVIE (see full ABBVIE pipeline at /company/abbvie).
What is the generic name of CREON?
PROTEASE) is the generic (nonproprietary) name of CREON.
What development phase is CREON in?
CREON is FDA-approved (marketed).
What are the side effects of CREON?
Common side effects of CREON include Headache, Contusion, Cough, Early Satiety, Abdominal Pain, Steatorrhea. Serious adverse events: Fibrosing Colonopathy, Distal Intestinal Obstruction Syndrome, Anaphylaxis, Asthma.
Related
- Manufacturer: ABBVIE — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing